CORTCorcept Therapeutics Incorporated

$4B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$147M+39.0% YoY

Gross Profit

$144M98.3% margin

Operating Income

$30M20.1% margin

Net Income

$28M18.9% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

+8.4%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$24M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$656M

Total Liabilities

$108M

Stockholders' Equity

$548M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$147M	$106M	+39.0%
Gross Profit	$144M	$104M	+38.4%
Operating Income	$30M	$15M	+98.6%
Net Income	$28M	$16M	+74.8%

CORT Q1 2024 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena